This is a working overview of nuclear receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-11-07. Anything still debated is marked as such rather than presented as settled.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also marketed informally as Stenabolic |
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ |
| Molecular formula | C24H30ClN3O4S | Approximate molecular weight 492 g/mol |
| CAS Registry Number | 1379686-30-2 | Identifier for the parent compound |
| Regulatory status | Not approved for human use | Prohibited in sport by WADA |
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Acetyl-CoA is generated in the mitochondria from pyruvate molecules derived from glucose via glycolysis. Within the mitochondria, acetyl-CoA typically combines with oxaloacetate and serves as a substrate for the synthesis of citrate as part of the well known citric acid cycle. Notably, the inner mitochondrial membrane is impermeable to acetyl-CoA, and as such, a specialized shuttle system must be used to import acetyl-CoA into the cytosol for fatty acid production. This process, known as the citrate–malate shuttle, relies on the tricarboxylate transport protein to import citrate into the cytosol, where it is then split into acetyl-CoA and oxaloacetate by the enzyme ATP citrate lyase (ACL). Cytosolic acetyl-CoA is then available for use in fatty acid and cholesterol synthesis, but oxaloacetate must be reduced to malate in order to reenter the mitochondria. Malate dehydrogenase reduces cytosolic oxaloacetate by coupling NADH oxidation to NAD+, and malate produced by this reaction can be transported back into the mitochondria, thus completing the namesake of the citrate–malate shuttle.
==== First state of emergency: July 1985 ==== On 20 July 1985, President Botha declared a partial state of emergency, effective from midnight, which he said would hold indefinitely in 36 townships around Johannesburg and in the eastern Cape. It was the first state of emergency since that imposed after the 1960 Sharpeville massacre, although a different variety of emergency regulation had also been imposed after the 1976 Soweto uprising. The death toll of the uprising was at that point estimated at 450 fatalities, and Botha said the emergency would combat "acts of violence and thuggery... mainly directed at the property and person of law-abiding black people". In a statement, he said:I wish to give the assurance that law-abiding people have nothing to fear. At the same time, I wish to issue a warning that strict action will be taken against those persons and institutions that cause or propagate disruption.The order gave the police and military "virtually unlimited" powers of search-and-seizure and arrest, as well as powers to seal off, impose curfews on, and censor news from the affected areas. During the first week, 1,000 activists were detained in the affected areas, and 16 people were killed. Despite the emergency, unrest continued in the Transvaal and eastern Cape and worsened elsewhere, particularly in Natal and the western Cape.
== Structure == The gene coding for DPEP1 is 6 kb long and consists of ten exons and nine introns. The protein itself is made of 411 amino acid residues and is only transcribed in kidney cells. Although disulfide linkages in DPEP1 do not contribute to the enzyme’s activity, they are essential for the enzyme’s proper function because they keep the enzyme’s subunits together and attached to the renal brush border. Cysteine 261 is involved in disulfide linkage between the enzyme’s subunits, and is also located very close to both the site of the GPI-anchor and the membrane, suggesting that it is also involved in the enzyme’s linkage to the membrane. DPEP1 is also a metalloenzyme that specifically uses zinc as its cofactor. The enzyme’s typical zinc content is 1.42 ug/mg. The addition of cobalt or manganese ions cause the enzyme to take on different conformations, which suggests that the enzyme may be able to hydrolyze different dipeptides depending on which metal ions are present—aka the metal-content of one’s micronutrient intake could affect their renal dipeptidase’s ability to metabolize various dipeptides.
== Human defensins == Initially human alpha defensin peptides were isolated from the neutrophils and are thus called human neutrophil peptides. Human neutrophil peptides are also known as α-defensins. Human neutrophil-derived alpha-defensins (HNPs) are capable of enhancing phagocytosis by mouse macrophages. HNP1-3 have been reported to increase the production of tumor necrosis factor (TNF) and IL-1, while decreasing the production of IL-10 by monocytes. Increased levels of proinflammatory factors (e.g., IL-1, TNF, histamine and prostaglandin D2) and suppressed levels of IL-10 at the site of microbial infection are likely to amplify local inflammatory responses. This might be further reinforced by the capacity of some human and rabbit alpha-defensins to inhibit the production of immunosuppressive glucocorticoids by competing for the binding of adrenocorticotropic hormone to its receptor. Moreover, human alpha-defensins can enhance or suppress the activation of the classical pathway of complement in vitro by binding to solid-phase or fluid-phase complement C1q, respectively. The capacity of defensins to enhance phagocytosis, promote neutrophil recruitment, enhance the production of proinflammatory cytokines, suppress anti-inflammatory mediators and regulate complement activation argues that defensins upregulate innate host inflammatory defenses against microbial invasion. Human neutrophil defensin-1, -3, and -4 are elevated in nasal aspirates from children with naturally occurring adenovirus infection.
Sources: en.wikipedia.org
The Swiss company GlycArt Biotechnology developed a system using CHO cells, where the cells were engineered to overexpress an enzyme called GnTIII. The effect of this overexpression is to block the formation of fucosylated oligosaccharides on the expressed antibodies. This technology was first reported in 1999 and was the basis of GlycArt Biotechnology. Roche acquired GlycArt in 2005 in order to acquire technology to afucosylate antibodies. GlycArt Biotechnology had been founded in 2000 as a spin-out company of the Swiss Federal Institute of Technology in Zurich. The first commercial product from the GlycArt acquisition was obinutuzumab, which as Gazyva gained FDA approval in November 2013 for the treatment of chronic lymphocytic leukemia. Kyowa Hakko Kirin's "Potelligent" platform uses a CHO cell line in which FUT8 has been knocked out, and which produces antibodies with little to no fucose in the Fc region. The company gained marketing approval in Japan in April 2012 for a monoclonal antibody drug called mogamulizumab which was developed using the platform. The Company's technology was first reported in 2004.
=== Material considerations === It is common to reduce a wood sample to just the cellulose component before testing, but since this can reduce the volume of the sample to 20% of its original size, testing of the whole wood is often performed as well. Charcoal is often tested but is likely to need treatment to remove contaminants. Unburnt bone can be tested; it is usual to date it using collagen, the protein fraction that remains after washing away the bone's structural material. Hydroxyproline, one of the constituent amino acids in bone, was once thought to be a reliable indicator as it was not known to occur except in bone, but it has since been detected in groundwater. For burnt bone, testability depends on the conditions under which the bone was burnt. If the bone was heated under reducing conditions, it (and associated organic matter) may have been carbonized. In this case, the sample is often usable. Shells from both marine and land organisms consist almost entirely of calcium carbonate, either as aragonite or as calcite, or some mixture of the two. Calcium carbonate is very susceptible to dissolving and recrystallizing; the recrystallized material will contain carbon from the sample's environment, which may be of geological origin. If testing recrystallized shell is unavoidable, it is sometimes possible to identify the original shell material from a sequence of tests. It is also possible to test conchiolin, an organic protein found in shell, but it constitutes only 1–2% of shell material. The three major components of peat are humic acid, humins, and fulvic acid.
Insulin analogues are recombinant proteins that are structurally based on human insulin but have been modified through amino acid substitutions or additions to alter their pharmacokinetic properties. These modifications are designed to either accelerate or prolong subcutaneous absorption while maintaining the biological function of insulin in regulating blood glucose levels. Native human insulin, commonly referred to as regular insulin, naturally assembles into hexamers, which must gradually dissociate into dimers and then monomers before they can be absorbed into the bloodstream. This process results in a delayed onset of action, making the timing of insulin administration a critical factor in diabetes management. Short-acting insulin analogues are developed to have a shorter duration of action than regular insulin, while long-acting insulin analogues are meant to have a peakless action profile and a prolonged duration of action.
Sources: en.wikipedia.org
== Behavior == As the common name suggests, croaking gouramis are capable of producing an audible grunting or chirping noise, accomplished through the use of specialized adaptations of their pectoral fins. These noises are produced by both sexes during breeding displays and during the establishment of dominance hierarchies among males. A typical showdown between males consists of each fish circling the other, flaring fins, aggressively darting (though rarely making contact), and producing croaking noises. Well-matched individuals may continue this behavior for several hours at a time.
Ofgem confirms that household energy prices will rise by 5% from January 2024. Lawrence Jones, founder of tech company UKFast Limited, is convicted of drugging and raping women in the early 1990s while he worked as a hotel pianist. 25 November A 200-metre stretch of road collapses onto a beach at Hemsby, Norfolk, due to coastal erosion, causing significant damage and disruption to the area. No casualties are reported. Another cliff collapse is reported further south, at Pakefield Holiday Park in Lowestoft, Suffolk. The public is urged to avoid the area, as local residents are evacuated. 26 November An estimated 100,000 people, including former prime minister Boris Johnson, attend a march against antisemitism in central London. Prophet Song, a dystopian novel set in Ireland and written by Paul Lynch, wins the 2023 Booker Prize. 27 November Health officials are investigating the first confirmed human case of the A(H1N2)v swine flu virus in the UK. Sunak cancels a planned meeting with Greek Prime Minister Kyriakos Mitsotakis after a diplomatic row breaks out between the UK and Greece over the Elgin Marbles. Downing Street subsequently says that the meeting was cancelled after Mitsotakis broke an agreement not to discuss the Marbles in public when he told BBC One's Sunday with Laura Kuenssberg he would like them to be returned. Police are investigating after Mirza Shahzad Akbar, a former adviser to imprisoned Pakistani prime minister Imran Khan, was attacked with acid outside his home in the UK.
2009: Chinese geneticist Zeng Fanyi and her research team published their experiment results proving that induced pluripotent stem cells can be used to generate whole mammalian bodies – in this case, live mice.
=== Fl–Fu === Edith M. Flanigen (born 1929), American chemist known for synthesizing emeralds and zeolites Nicolas Flamel (c. 1330–1418), French alchemist who was believed to have created and discovered the philosopher's stone Paul Flory (1910–1985), American chemist, 1974 Nobel Prize in Chemistry for work on the physical chemistry of macromolecules Maria Forsyth (PhD 1990), Australian chemist known for work on energy storage and on corrosion Margaret D.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.
No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.
The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.